TIM-3

[Blood] Scientists used high-resolution flow- and mass cytometry to examine NK cell repertoires in 64 patients with neutropenia and 27 healthy age- and gender-matched donors.

[Leukemia & Lymphoma] The authors investigated the prognostic significance of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) in t(8;21) acute myeloid leukemia (AML). A total of 47 t(8;21) AML patients were tested for TIM-3 expression by multi-parameter flow cytometry at diagnosis.

[Reproductive Sciences] Using a tube formation assay between HTR8/SVneo cells and human umbilical vein endothelial cells, scientists found that Tim-3 pathway blockade inhibits tube formation and reversed by addition of recombinant IL-4 and/or IL-10.

[Cancer Immunology, Immunotherapy] To determine the immune-modulatory influence of CSC in small cell lung cancer (SCLC), scientists focused on the characterization of CD44+CD90+ CSC-like subpopulations in SCLC.

[Science Signaling] Investigators examined the upstream signaling pathways that control Tim-3–mediated increases in phosphorylated S6 in T cells. They defined the localization of Tim-3 relative to the T cell immune synapse and its effects on downstream signaling.

[British Journal of Cancer] The authors critically discuss current knowledge regarding predictive biomarkers for checkpoint inhibitor-based immunotherapy, highlight the missing/unclear links and emphasise the importance of characterising each neoplasm and its microenvironment in order to better guide the course of treatment.